ROQ.L
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Industry
Biotechnology
IPO Date
2021-03-22
Stock Exchange
LSE
Ticker
ROQ.L
According to Roquefort Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 2.19M. This represents a change of -68.37% compared to the average of 6.92M of the last 4 quarters.
The mean historical Enterprise Value of Roquefort Therapeutics plc over the last ten years is 5.09M. The current 2.19M Enterprise Value has changed 4.20% with respect to the historical average. Over the past ten years (40 quarters), ROQ.L's Enterprise Value was at its highest in in the December 2023 quarter at 9.36M. The Enterprise Value was at its lowest in in the June 2022 quarter at -119239.57.
Average
5.09M
Median
4.92M
Minimum
1.69M
Maximum
8.83M
Discovering the peaks and valleys of Roquefort Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 167.57%
Maximum Annual Enterprise Value = 8.83M
Minimum Annual Increase = -39.83%
Minimum Annual Enterprise Value = 1.69M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 5.31M | -39.83% |
| 2023 | 8.83M | 94.73% |
| 2022 | 4.53M | 167.57% |
The current Enterprise Value of Roquefort Therapeutics plc (ROQ.L) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.22M
5-year avg
5.09M
10-year avg
5.09M
Roquefort Therapeutics plc’s Enterprise Value is greater than Physiomics Plc (610.30K), less than Theracryf Plc (2.40M), greater than ValiRx plc (-327491.00), greater than Polarean Imaging plc (-8870797.37), less than CRISM Therapeutics Corporation (5.38M), less than Tissue Regenix Group plc (15.48M), greater than Feedback plc (-2510297.00), less than Cizzle Biotechnology Holdings Plc (5.98M), less than Proteome Sciences plc (22.80M), greater than MyHealthChecked PLC (-504856.00),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 610.30K | N/A | |
| 2.40M | N/A | |
| -327491.00 | N/A | |
| -8870797.37 | N/A | |
| 5.38M | N/A | |
| 15.48M | N/A | |
| -2510297.00 | N/A | |
| 5.98M | N/A | |
| 22.80M | N/A | |
| -504856.00 | N/A |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Roquefort Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Roquefort Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Roquefort Therapeutics plc's Enterprise Value?
What is the highest Enterprise Value for Roquefort Therapeutics plc (ROQ.L)?
What is the 3-year average Enterprise Value for Roquefort Therapeutics plc (ROQ.L)?
What is the 5-year average Enterprise Value for Roquefort Therapeutics plc (ROQ.L)?
How does the current Enterprise Value for Roquefort Therapeutics plc (ROQ.L) compare to its historical average?